Jason V. Coloma, Chief Executive Officer and Director of Maze Therapeutics, Inc. (NASDAQ:MAZE), filed a Form 4 on September 4, 2026, disclosing four sales of common stock on September 2 and September 3, 2026, executed to satisfy tax withholding obligations tied to vesting restricted stock units.

Key Highlights

  • Purpose of sales: According to the filing, all reported transactions represent shares sold to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units.
  • September 2 sales: Coloma disposed of 9,852 shares at a weighted average price of $26.376 per share and 1,375 shares at a weighted average price of $27.1211 per share.
  • September 3 sales: Coloma disposed of 11,282 shares at a weighted average price of $26.0133 per share and 129 shares at $25.7749 per share.
  • Direct ownership after transactions: Following all four reported sales, Coloma directly held 27,362 shares of common stock.
  • Indirect holdings: The filing reports 18,151 shares held indirectly through The Coloma 2021 Irrevocable Trust and 223,355 shares held indirectly through the Coloma Family Trust, with Coloma and his spouse serving as co-trustees of each.
  • Weighted average prices: The September 2 first tranche ranged from $26.03 to $27.00 per share; the September 2 second tranche ranged from $27.055 to $27.40 per share; the September 3 first tranche ranged from $25.743 to $26.65 per share.

RSU Vesting Drives Coloma's Multi-Day Share Sales at Maze Therapeutics

According to the Form 4 filed with the SEC, Jason V. Coloma, who serves as both Chief Executive Officer and Director of Maze Therapeutics, Inc., sold a combined total of four tranches of common stock across two consecutive trading days. The filing states that each of these dispositions carries transaction code "S" and was made specifically to cover tax withholding obligations arising from restricted stock unit vesting, not as open-market discretionary sales initiated independently of a compensation event.

On September 2, 2026, the filing discloses two separate transactions. The first involved 9,852 shares disposed of at a weighted average price of $26.376 per share, with individual transaction prices ranging from $26.03 to $27.00 per share. The second involved 1,375 shares at a weighted average of $27.1211 per share, with prices ranging from $27.055 to $27.40 per share. On September 3, 2026, a further 11,282 shares were sold at a weighted average of $26.0133 per share (range: $25.743 to $26.65), followed by 129 shares at $25.7749 per share.

After all four transactions, the filing reports Coloma's direct beneficial ownership stood at 27,362 shares. In addition, the filing identifies two pools of indirectly held shares: 18,151 shares through The Coloma 2021 Irrevocable Trust and 223,355 shares through the Coloma Family Trust, both of which list Coloma and his spouse as co-trustees. The Form 4 was signed by Courtney Phillips as attorney-in-fact and dated September 4, 2026.

What Was Disclosed

The filing covers four dispositions of Maze Therapeutics common stock by CEO Jason V. Coloma on September 2 and 3, 2026, totaling 22,638 shares sold at weighted average prices between $25.7749 and $27.1211 per share, all attributed to RSU-vesting tax withholding obligations.